Phathom Pharmaceuticals, Inc. 8-K

What Happened

• Phathom Pharmaceuticals, Inc. announced its quarterly financial results for the period ended March 31, 2026 in a press release issued April 30, 2026. The company furnished that press release under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K.

Key Details

• Filing date: April 30, 2026 (Form 8-K).
• Reporting period: Quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 to the 8-K.
• The submission includes an Inline XBRL cover page (Exhibit 104). Per General Instruction B.2 of Form 8-K, the information furnished (including Exhibit 99.1) is not “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.

Why It Matters

• The press release contains the company’s reported quarterly results—such as earnings, revenue and other financial metrics—that investors rely on to assess performance and outlook. Investors should review Exhibit 99.1 (the April 30 press release) and any related SEC filings for the detailed figures and commentary.
• Because the information is furnished (not “filed”), it carries different legal treatment under the Exchange Act; investors should consult the press release and subsequent filings for any forward-looking statements, guidance or more detailed financial disclosures.